Attention-deficit Hyperactivity Disorder Therapeutics Market

Attention-deficit/hyperactivity disorder (ADHD) is a disorder marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.

Inattention means a person wanders off task, lacks persistence, has difficulty sustaining focus, and is disorganized; and these problems are not due to defiance or lack of comprehension.
Hyperactivity means a person seems to move about constantly, including in situations in which it is not appropriate; or excessively fidgets, taps, or talks. In adults, it may be extreme restlessness or wearing others out with constant activity.
Impulsivity means a person makes hasty actions that occur in the moment without first thinking about them and that may have a high potential for harm, or a desire for immediate rewards or inability to delay gratification. An impulsive person may be socially intrusive and excessively interrupt others or make important decisions without considering the long-term consequences.
Attention-deficit Hyperactivity Disorder Therapeutics Market aims to provide a comprehensive presentation of the global market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics. Attention-deficit Hyperactivity Disorder Therapeutics Market contains market size and forecasts of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics in global, including the following market information:
Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Stimulants Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics include Pfizer, GSK, Eli Lilly, Novartis, Johnson & Johnson, Mallinckrodt, Hisamitsu, UCB and Takeda, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Segment Percentages, by Type, 2022 (%)
Stimulants
Non-stimulants
Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Segment Percentages, by Application, 2022 (%)
Pediatric and Adolescents
Adults
Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
GSK
Eli Lilly
Novartis
Johnson & Johnson
Mallinckrodt
Hisamitsu
UCB
Takeda
Purdue Pharma
Impax Laboratories
Outline of Major Chapters:
Chapter 1: Introduces the definition of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics, market overview.
Chapter 2: Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.